Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma

Overview

This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with refractory multiple myeloma.

Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop tumor cells from growing. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pomalidomide and dexamethasone are more effective with or without ixazomib in treating multiple myeloma.

SparkCures ID 472
Trial Phase Phase 1/2
Enrollment 73 Patients
Treatments
Trial Sponsors
  • Alliance for Clinical Trials in Oncology
Trial Collaborators
  • National Cancer Institute (NCI)
  • Celgene Corporation
  • Millennium Pharmaceuticals, Inc.
NCT Identifier

NCT02004275

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Eligibility Criteria:

  1. Documentation of Disease: Histologically confirmed diagnosis of symptomatic multiple myeloma.
  2. Measurable disease:
    1. Serum M-protein ≥ 1.0 g/dL and/or
    2. Urine M-protein ≥ 200 mg/24 hours and/or
    3. Involved serum free light chain level ≥ 10 mg/dL and an abnormal serum free light chain ratio and/or
    4. Baseline marrow burden of myeloma of at least 30%
  3. Prior Treatment:
    1. Previously treated symptomatic multiple myeloma
    2. Lenalidomide and proteasome inhibitor-refractory multiple myeloma (dual refractory disease)
      • Lenalidomide and proteasome inhibitor-refractory disease is defined as disease progression on or progression within 60 days of the last dose of a lenalidomide and proteasome inhibitor-based treatment.
      • Patients should have received at least 2 cycles of a lenalidomide or proteasome inhibitor-based regimen at standard doses to be evaluable for refractoriness.
      • Patients can be refractory to either bortezomib or carfilzomib they do not need to be refractory to both.
      • Patients can be refractory to lenalidomide and proteasome inhibitors given sequentially as part of different lines of therapy or therapy that includes a combination of lenalidomide and a proteasome inhibitor.
    3. At least 2 or more prior lines of systemic therapy for multiple myeloma
      • A line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy, as well as a planned series of treatment regimens administered in a sequential manner (e.g. lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy).
      • A new line of therapy begins when a planned therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, disease relapse or treatment-related toxicity (e.g. a patient is progressing in the face of lenalidomide maintenance therapy and has bortezomib and dexamethasone added into their regimen).
      • A new line of therapy also begins when a planned treatment-free interval is interrupted by the need to start treatment due to disease relapse/progression (e.g. a patient with relapsed myeloma achieves a partial response after a planned 8 cycles of cyclophosphamide, bortezomib and dexamethasone, enjoys an 8-month period off therapy but then experiences disease progression requiring re-initiation of therapy).
    4. Allogeneic stem cell transplantation is allowed provided the patient is ≥ 1 year from transplant, is not on immunosuppressive therapy to treat/prevent graft-versus-host disease, has no evidence of active graft versus host disease, no evidence of active infection and meets all other criteria for participation.
    5. No other chemotherapy or radiation therapy within 14 days prior to registration
    6. No investigational agent within 21 days prior to registration
    7. Pomalidomide naïve and pomalidomide sensitive disease are allowed during phase I and phase II
      • Sensitivity to pomalidomide is defined as an MR or better to prior pomalidomide-based therapy that is maintained for ≥60 days from the last dose of therapy.
    8. No concurrent investigational therapy
    9. No major surgery within 28 days prior to registration
    10. Patients cannot have received G-CSF (Filgrastim) or GM-CSF (Sargramostim) within 1 week of screening or Pegfilgrastim within 2 weeks of screening to meet eligibility criteria
  4. Non-pregnant and non-nursing:
    1. Women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mlU/ml no more than 14 days prior to therapy and repeated again within 24 hours of starting pomalidomide
    2. Women of childbearing potential must either commit to complete abstinence from heterosexual contact or begin two acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, at the same time, before starting pomalidomide
    3. Females of childbearing potential must agree to ongoing pregnancy testing.
    4. Men must practice complete abstinence or agree to use a condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy.
    5. All participants must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
    6. Participating women cannot be pregnant or nursing
  5. A female of childbearing potential is a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
  6. ≥18 years of age
  7. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
  8. Required Initial Laboratory Values:
    1. Absolute Neutrophil Count (ANC) ≥ 1.0 x 10^9/L
    2. Platelet Count ≥ 50 x 10^9/L
    3. Calculated Creatinine Clearance* ≥ 50 mL/min
    4. Total Bilirubin < 1.5 x upper limits of normal (ULN)
    5. AST and ALT < 2.5 x upper limits of normal (ULN)
      • Calculated utilizing the Cockcroft-Gault formula or 24-hour urine collection
  9. Intercurrent or Recent Illness:
    1. No central nervous system involvement
    2. No primary refractory multiple myeloma
      • primary refractory multiple myeloma is defined as disease that is nonresponsive - patients who have never achieved a minimal response (MR) or better - with any therapy over the course of their disease
      • primary refractory multiple myeloma also includes patients who never achieve minimal response (MR) or better in whom there is no significant change in M-protein and no evidence of clinical progression as well as patients who meet criteria for true progressive disease (PD)
    3. No primary or secondary plasma cell leukemia
    4. No amyloid light-chain (AL) amyloidosis or polyneuropathy, organomegaly, endocrinopathy, monoclonal, gammopathy and skin changes (POEMS) syndrome
    5. No known active hepatitis C based on +HCV antibody (confirmed), +HCV ribonucleic acid (RNA) and liver disease with history of positive serology
    6. No known hepatitis B surface antigen positivity
    7. No previous hypersensitivity to any of the components of the study treatment
    8. No prior history of erythema multiforme with thalidomide or lenalidomide treatment
  10. Peripheral Neuropathy ≤ Grade 2
  11. Adequate cardiac function defined as:
    1. No electrocardiography (EKG) evidence of acute ischemia
    2. No EKG evidence of active, clinically significant conduction system abnormalities
    3. No EKG evidence of >Grade 2 (>480 ms) quantum tunnelling composite (QTc) prolongation
    4. Prior to study entry, any EKG abnormality at screening not felt to put the patient at risk has to be documented by the investigator as not medically significant
    5. No uncontrolled angina or severe ventricular arrhythmias
    6. No clinically significant pericardial disease
    7. No history of myocardial infarction within the last 6 months
    8. No Class 3 or higher New York Heart Association Congestive Heart Failure
  12. Concomitant Treatment - Patients cannot be on strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2.
    • Ixazomib is a substrate of CYP3A4 and CYP1A2. For additional information about potential drug-drug and drug-food interactions with ixazomib, please see the protocol.
    • Strong CYP3A4 inducers prohibited (examples):
      • phenytoin
      • carbamazepine
      • rifampin
      • rifabutin
      • rifapentin
      • phenobarbital
      • St. John's Wort
    • Strong CYP3A4 inhibitors are prohibited:
      • boceprevir
      • indinavir
      • nelfinavir
      • lopinavir
      • saquinavir
      • telaprevir
      • ritonavir
      • clarithromycin
      • conivaptan
      • itraconazole
      • ketoconazole
      • mibefradil
      • nefazodone
      • posaconazole
      • voriconazole
      • telithromycin
    • Strong CYP1A2 inhibitors are prohibited:
      • fluvoxamine
      • ciprofloxacin
  13. Human Immunodeficiency virus (HIV) infection - Patients with HIV infection are eligible, provided they meet the following:
    1. No history of Acquired Immune Deficiency Syndrome (AIDS)-defining conditions or other HIV related illness
    2. CD4+ cells nadirs > 350/mm^3
    3. Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3

Please note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4.

Resources

There are no resources, links or videos to display for this clinical trial.